Fig. 2From: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial a Sustained response rate (PGI-I score ≤ 2 on two consecutive evaluations by phone interview). b Response rate based on subjects reporting a PGI-I score ≤ 2 and c change in HDRS-17 score in the total ITT population. TC: telephone controls; # p < 0.1; *p < 0.05Back to article page